Who are Eicosapentaenoic acid gastro-resistant capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epanova, Omega-3-acid ethyl esters 90, Omacor®, Antara (fenofibrate) + Lovaza, fenofibrate/omega, Product 3 - Standard Fish Oil Triglyceride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eicosapentaenoic-acid-gastro-resistant-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Eicosapentaenoic acid gastro-resistant capsules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eicosapentaenoic acid gastro-resistant capsules (Eicosapentaenoic acid gastro-resistant capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid. Area: Cardiovascular.

phase 3 Omega-3 fatty acid Multiple targets including triglyceride metabolism and inflammatory pathways Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Eicosapentaenoic acid gastro-resistant capsules (Eicosapentaenoic acid gastro-resistant capsules) — S.L.A. Pharma AG. Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways in cardiovascular disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eicosapentaenoic acid gastro-resistant capsules TARGET	Eicosapentaenoic acid gastro-resistant capsules	S.L.A. Pharma AG	phase 3	Omega-3 fatty acid	Multiple targets including triglyceride metabolism and inflammatory pathways
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
Omega-3-acid ethyl esters 90	Omega-3-acid ethyl esters 90	Pronova BioPharma	marketed	Fibrate-like lipid-lowering agent / Omega-3 fatty acid
Omacor®	Omacor®	Hospital Universitari Vall d'Hebron Research Institute	marketed	Omega-3 fatty acid	Hepatic triglyceride synthesis pathway
Antara (fenofibrate) + Lovaza	Antara (fenofibrate) + Lovaza	GlaxoSmithKline	marketed	Fibrate + Omega-3 fatty acid combination	PPARα (fenofibrate); GPR120, GPR40 (omega-3 fatty acids)
fenofibrate/omega	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)
Product 3 - Standard Fish Oil Triglyceride	Product 3 - Standard Fish Oil Triglyceride	RDC Clinical Pty Ltd	marketed	Omega-3 fatty acid supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid class)

Estudios Clínicos Latino América · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
S.L.A. Pharma AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eicosapentaenoic acid gastro-resistant capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/eicosapentaenoic-acid-gastro-resistant-capsules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab